within Pharmacolibrary.Drugs.ATC.P;

model P01AX06
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.23,
    Cl             = 2.4999999999999998e-06,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0088,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600,            
    Vdp             = 0.0053,
    k12             = 0.056,
    k21             = 0.056
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P01AX06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Atovaquone is a hydroxynaphthoquinone antiprotozoal medication primarily used for the treatment and prevention of Pneumocystis jirovecii pneumonia (PCP), toxoplasmosis, and in combination with proguanil for malaria treatment and prophylaxis. It is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic model of atovaquone in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Darade, A, et al., &amp; Patravale, V (2018). Atovaquone oral bioavailability enhancement using electrospraying technology. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 111 195–204. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2017.09.051\">10.1016/j.ejps.2017.09.051</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28974387/\">https://pubmed.ncbi.nlm.nih.gov/28974387</a></p></li><li><p>Haile, LG, &amp; Flaherty, JF (1993). Atovaquone: a review. <i>The Annals of pharmacotherapy</i> 27(12) 1488–1494. DOI:<a href=\"https://doi.org/10.1177/106002809302701215\">10.1177/106002809302701215</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8305784/\">https://pubmed.ncbi.nlm.nih.gov/8305784</a></p></li><li><p>Yang, E, et al., &amp; Lee, S (2023). Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. <i>Clinical pharmacokinetics</i> 62(4) 599–608. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01228-4\">10.1007/s40262-023-01228-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36897544/\">https://pubmed.ncbi.nlm.nih.gov/36897544</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P01AX06;
